About: Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19)
Creator	Yousefi, Mehdi Kafil, Hossein Esposito, Isabella Espsoito, Silvano Ganbarov, Khudaverdi Khodadadi, Ehsan Khodadadi, Ehsaneh Maroufi, Parham Zeinalzadeh, Elham Zeinalzadeh7, Elham
Source	Elsevier; Medline; PMC
abstract	The recent epidemic outbreak of a novel human coronavirus called SARS-CoV-2 and causing the respiratory tract disease COVID-19 has reached worldwide resonance and a global effort is being undertaken to characterize the molecular features and evolutionary origins of this virus. Therefore, rapid and accurate identification of pathogenic viruses plays a vital role in selecting appropriate treatments, saving people's lives and preventing epidemics. Additionally, general treatments, coronavirus-specific treatments, and antiviral treatments useful in fighting COVID-19 are addressed. This review sets out to shed light on the SARS-CoV-2 and host receptor recognition, a crucial factor for successful virus infection and taking immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein of SARS-CoV-2. A variety of improved or new approaches also have been developed. It is anticipated that this will assist researchers and clinicians in developing better techniques for timely and effective detection of coronavirus infection. Moreover, the genomic sequence of the virus responsible for COVID-19, as well as the experimentally determined three-dimensional structure of the Main protease (Mpro) is available. The reported structure of the target Mpro was described in this review to identify potential drugs for COVID-19 using virtual high throughput screening.
has issue date	2020-05-05(xsd:dateTime)
bibo:doi	10.1016/j.micpath.2020.104241
bibo:pmid	32387389
has license	no-cc
sha1sum (hex)	4d84c93094f3a3c9c3acf73ffd15c6f9cfb3a059
schema:url	https://doi.org/10.1016/j.micpath.2020.104241
resource representing a document's title	Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19)
has PubMed Central identifier	PMC7199731
has PubMed identifier	32387389
schema:publication	Microb Pathog
resource representing a document's body	covid:4d84c93094f3a3c9c3acf73ffd15c6f9cfb3a059#body_text
is schema:about of	named entity 'coronavirus' named entity 'protein-protein interaction' named entity 'protease' named entity 'accurate' named entity 'reached' named entity 'preventing' named entity 'virus' named entity 'researchers' named entity 'proteins' named entity 'structure' named entity 'predict' named entity 'Covid-19' named entity 'antiviral' named entity 'DESCRIBED' named entity 'MOLECULAR' named entity 'VIRUS' named entity 'APPROACHES' named entity 'GLOBAL' named entity 'OUTBREAK' named entity 'origins' named entity 'rapid' named entity 'SARS-CoV-2' named entity 'potential' named entity 'emerging' named entity 'clinicians' named entity 'human' named entity 'functions' named entity 'SARS-CoV-2' named entity 'protein' named entity 'The' named entity 'Covid-19' named entity 'Sars-CoV-2' named entity 'Study' named entity 'glycoprotein' named entity 'virus' named entity 'epitopes' named entity 'COVID-19' named entity 'human coronavirus' named entity 'protease' named entity 'coronavirus' named entity '3D structures' named entity 'COVID-19' named entity 'Covid' named entity 'helical' named entity 'active site' named entity 'ACE2' named entity 'protein' named entity 'DPP4' named entity 'single-cell' named entity 'COVID-19' named entity 'Pancreatic disease' named entity 'measles' named entity 'class I fusion protein' named entity 'Membrane proteins' named entity 'zinc' named entity 'receptor binding' named entity 'antibody' named entity 'molecular pathways' named entity 'Antioxidant' named entity 'serotonin receptor' named entity 'vaccine design' named entity 'membrane fusion' named entity 'ACE2' named entity 'design and development' named entity 'gene expression' named entity 'host cells' named entity 'pathogen' named entity 'Viruses' named entity 'RNA-binding' named entity 'leader RNA' named entity 'receptor binding' named entity 'embryo'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software